- Ticker
- ACARIX.ST
- Price
- 0.83
- Stock movement down
- -0.01 (-1.43%)
- Company name
- Acarix A/S
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Medical Devices
- Market cap
- 208.88M
- Ent value
- 152.12M
- Price/Sales
- 47.89
- Price/Book
- 2.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -37.74%
- 3 year return
- -20.57%
- 5 year return
- -34.79%
- 10 year return
- -
Last updated: 2022-08-25
DIVIDENDS
ACARIX.ST does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 47.89 |
| Price to Book | 2.42 |
| EV to Sales | 34.87 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 251.97M |
| EPS (TTM) | -0.22 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.36M |
| Gross profit (TTM) | 3.35M |
| Operating income (TTM) | -54.76M |
| Net income (TTM) | -54.85M |
| EPS (TTM) | -0.22 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.71% |
| Operating margin (TTM) | -1255.36% |
| Profit margin (TTM) | -1257.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 68.74M |
| Net receivables | 9.78M |
| Total current assets | 81.98M |
| Goodwill | 0.00 |
| Intangible assets | 15.71M |
| Property, plant and equipment | 0.00 |
| Total assets | 98.28M |
| Accounts payable | 629.00K |
| Short/Current long term debt | 448.00K |
| Total current liabilities | 11.81M |
| Total liabilities | 11.98M |
| Shareholder's equity | 86.31M |
| Net tangible assets | 82.33M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -54.98M |
| Capital expenditures (TTM) | 202.00K |
| Free cash flow (TTM) | -55.18M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -63.56% |
| Return on Assets | -55.81% |
| Return on Invested Capital | -63.35% |
| Cash Return on Invested Capital | -63.73% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.82 |
| Daily high | 0.84 |
| Daily low | 0.75 |
| Daily Volume | 1.58M |
| All-time high | 9.18 |
| 1y analyst estimate | 2.40 |
| Beta | 2.24 |
| EPS (TTM) | -0.22 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 10 Nov 2022 |
Downside potential
Loading...
Downside potential data
| ACARIX.ST | S&P500 | |
| Current price drop from All-time high | -90.97% | -12.18% |
| Highest price drop | -94.86% | -56.47% |
| Date of highest drop | 16 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -72.05% | -11.38% |
| Avg time to new high | 287 days | 12 days |
| Max time to new high | 1428 days | 1805 days |
COMPANY DETAILS
Marketcap
208.88M
Marketcap category
Small-cap
Description
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Press release Malmö, Sweden, June 22, 2022 Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska Acarix continues its US expansion by partnering with Strategic...
June 22, 2022
Press release Malmö, Sweden, June 10, 2022 Acarix signs additional commercial agreement in US and receives order for CADScor®System in Louisiana. Acarix continues the US expansion with another commerc...
June 10, 2022
Press release Malmö, Sweden, June 3, 2022 Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee Acarix today announces an additional commercial...
June 3, 2022
Press release Malmö, Sweden, May 11, 2022 Announcement from Acarix's annual general meeting The annual general meeting 2022 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 20...
May 11, 2022
Press release Malmö, Sweden, May 11, 2022 Acarix AB (publ) publishes Interim Report, January – March 2022 Increased commercial momentum and great interest in CADScor® System on the US market2022 has s...
May 11, 2022
Press release Malmö, Sweden, May 6, 2022 Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and CEO of Acarix AB (publ), will present at the Naventus Health Care Summ...
May 6, 2022
Press release Malmö, Sweden, April 20, 2022 Acarix publishes the annual report for 2021 Today, Wednesday April 20, Acarix is publishing its Annual Report for 2021 on the company website www.acarix.com...
April 20, 2022
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 11 May 202...
April 11, 2022
Press release (MAR)Malmö, Sweden, April 1, 2022 FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis The Food and Drug Administration (FDA) ha...
April 1, 2022
Press release (MAR)Malmö, Sweden, March 11, 2022 Acarix receives strategic order for the CADScor®System in US Acarix today announces first order of the CADScor®System in the US from Apex Heart and Vas...
March 11, 2022
Next page